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Purpose:Most clinical end points after endovascular aneurysm repair (EVAR) are endograft-specific, but type II endoleaks
have been assumed to be an unavoidable consequence of the repair method and independent of the type of endograft
used. Some recent data have suggested that the rate of type II endoleaks may also be graft-dependent. We reviewed a large
clinical experience with six endografts to determine the behavior of type II endoleaks and whether they are graft-specific.
Methods: All elective EVAR cases from five university institutions from 1996 to 2003 were retrospectively analyzed.
Endografts used in <50 patients were excluded. Endoleaks were diagnosed and classified from contrast-enhanced
computed tomography (CT) scans by the treating surgeons. Results of angiography and interventions for endoleaks were
tracked. The rate of type II endoleaks was compared among endografts at 1, 6, and 12 months, and yearly thereafter.
Statistical significance was defined as P < .05.
Results:During the study period, 1909 patients underwent elective EVAR and had an adequate imaging follow-up at one
of the specified time points. At 1 month, the overall rate of type II endoleak was 14.0% (range, 9.8% to 25.2%.) The
Excluder had a significantly higher incidence of type II endoleaks at 1 month but was similar to most other grafts during
longer follow-up. At 6 months, the overall rate of type II endoleak was 16.3% (range, 8.3% to 16.8%). The Talent and
Lifepath had an apparent lower initial rate of type II leaks, but this was only significant for the Talent at 6 months
compared with Excluder, Zenith, and Ancure, and at 1 year compared with Excluder and Zenith. No graft had a
long-term statistically significant difference in the rate of type II endoleak formation. Intervention rates varied by
institution and graft type but in general were quite low. Of 25 successful interventions (Ancure, 12; AneuRx, 8; Excluder,
2; Lifepath, 2; Zenith, 1; Talent, 0), 21 were performed during the first year. Interim spontaneous resolution, defined as
a negative CT scan after a CT positive for endoleak, was high, especially in the first year. Resolution of type II endoleaks
occurred in 54 (33%) of 164 between 1 and 6 months, in 37 (33%) of 112 between 6 and 12 months, in 20 (35%) of 57
from 12 to 24 months, and in 5 (20%) of 25 between 24 and 36months. The various grafts had a nearly identical pattern,
but the rates were highest for the Talent. Late appearing endoleaks, defined as a positive CT after a negative CT, were
frequent. At 6 months, 44 (30%) of 147 type II endoleaks were newly diagnosed. The rates were 37 (35%) of 107 at 12
months, 15 (27%) of 56 at 2 years and 5 (25%) of 20 at 3 years. No conversions to open repair for type II endoleaks were
noted in the first 4 years. The thrombus burden could not be determined in this analysis.
Conclusions: Type II endoleaks occur in nearly 15% of patients treated by EVAR. The early incidence varies only slightly
with graft type. The long-term prevalence and clinical significance are masked by different treatment patterns,
spontaneous resolution, newly evident endoleaks, and aneurysm size at initial treatment. (J Vasc Surg 2006;43:657-61.)Endoleaks continue to be a common and vexing com-
plication after endovascular aneurysm repair (EVAR). Some
may be innocuous, but the detection of an endoleak during
postoperative follow-up frequently requires increased surveil-
lance to ensure no adverse sequelae such as aneurysm
enlargement occur. Although the etiology is multifactorial,
some endoleaks are clearly related to the endograft used. In
addition to anatomic factors such as short and angulated
necks, type I leaks are also related to the design of the
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Type III, noted most frequently with modular grafts, are
associated with the length of overlap as well as with fabric
thickness and method of attachment of the metallic stents.
Type IV endoleaks occur only with endografts with a
semi-porous fabric.
Type II endoleaks, arising from branches of the aorta,
have long been assumed to be procedure-specific and inde-
pendent of the particular stent-graft used. Although the
number and size of patent branches has been linked to the
incidence of type II perigraft flow, recent reports1-3 suggest
that the rates also vary significantly among endografts. This
study was undertaken to compare the incidence of type II
endoleaks between different endografts of various charac-
teristics to determine if significant differences exist.
METHODS
All elective EVAR cases from five university institutions
from 1996 to 2003 were retrospectively analyzed for oc-
currence of type II endoleak. After institutional review
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or spreadsheets were sent to the first author for compilation
of data.
Endoleaks were determined and classified to the best
estimation by the treating surgeons at individual institu-
tions based on contrast-enhanced computed tomography
(CT) scanning as specified by institution protocol. Ex-
cluded were endografts used in 50 patients after data
from all institutions were combined. Also excluded were
patients who could not be monitored by contrast enhanced
CT and those treated for ruptured abdominal aortic aneu-
rysms (AAAs). Further interrogation or interventions for
treatment of the endoleaks were also reviewed and tabu-
lated.
Data were pooled on the basis of device type, which
included the Excluder (W.L.Gore and Associates, Flag-
staff, Ariz), Ancure (Guidant, Menlo Park, Calif), AneuRx
(Medtronic, Santa Rosa, Calif), Zenith (Cook Blooming-
ton, Ind), Talent (Medtronic, Sunrise, Fla), and Lifepath
(Edwards Life Sciences, Irvine, Calif) endografts. A distinc-
tion was not made between those patients treated as part of
an investigational device exemption trial or those treated
after market approval.
Preoperative anatomic features (ie, aneurysm diameter,
side branch patency, neck angulation) and thrombus bur-
den were not assessed. The incidence of type II endoleak
and rate of interventions were tracked at 1, 6, and 12
months, and yearly thereafter. Rates for spontaneous reso-
lution and late appearing endoleaks were calculated and
compared. Spontaneous resolution was defined as a CT scan
that showed no evidence of endoleak after a CT revealing
Table I. Rate of type II endoleaks by graft type for the fir
1 month
Type II Total % Type I
Talent 22 182 12.1 15
Lifepath 8 81 9.8% 6
Excluder 28 111 25.2* 16
Zenith 45 370 12.2 30
AneuRx 61 444 13.7 48
Ancure 57 393 14.5 32
Total 221 1581 14.0 147
* P  .05.
Table II. Rate of type II endoleak by endograft type betw
24 months
Type II Total % Type I
Talent 1 118 0.8% 0
Excluder 8 55 14.5% 5
Zenith 3 43 7.0%
AneuRx 29 210 13.8% 13
Ancure 15 213 7.0% 2
Total 56 639 8.8% 20an endoleak, without intervention in the intervening time.Late appearing endoleaks were defined as a positive CT
scan after an initial negative CT. Rates of endoleak by
graft type at each time point and the overall rate of inter-
ventions were compared with 2 analysis, and statistical
significance was set at P  .05.
RESULTS
During the study period, 1909 patients underwent
elective EVAR and had an adequate imaging follow-up at
one of the specified follow-up time points. The rates during
the first year are presented in Table I. At 1 month, the
overall rate of type II endoleak was 14% (range, 9.8% to
25.2%). Only one endograft, the Excluder, had a statisti-
cally significant higher rate of type II leaks at this early
observation period. This difference was short lived, how-
ever, as the rates at 6 and 12 months were essentially
identical to most of the other grafts. The overall rate of type
II endoleak did not change significantly at 6 months
(16.3%), but the Talent endograft did have a significantly
lower rate compared with Excluder, Zenith, and Ancure
and maintained significance against the Excluder and
Zenith at 1 year. The Lifepath appeared to have a lower rate
of type II endoleak but failed to reach statistical significance
compared with the other grafts. The rates of type II en-
doleaks were also calculated up to 4 years after implantation
(Table II). However, as a result of interim interventions,
the significance of the data at the later time points is not
fully comparable among the grafts. A Kaplan-Meier life-
table analysis shows no significant difference in overall rate
of type II endoleaks by grafts over a 2-year period (Fig 1).
Intervention rates varied by institution and graft type
r of follow-up
6 months 12 months
Total % Type II Total %
181 8.3* 10 159 6.2*
61 9.8 4 57 7.0
95 16.8 13 86 15.1
193 15.5 19 124 15.3
350 13.7 34 327 10.4
215 14.8 27 295 9.2
901 16.3 107 1048 10.2
2 and 4 years
36 months 48 months
Total % Type II Total %
113 0.0%
36 13.9% 2 22 9.1%
92 14.1% 2 29 6.9%
121 1.6% 2 43 4.7%
362 5.5% 6 94 6.4%st yea
Ieen
Ibut in general were quite low. Of 25 successful interven-
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Zenith, 1; Talent, 0), 21 were performed during the first
year. Rates of attempted interventions varied at each insti-
tution (range, 2.9% to 7.6%) (Table III), but overall, were
not statistically different. This differential policy by institu-
tion on type II endoleaks was also reflected in the rates of
interventions by graft type, as each center had a predomi-
nance of one graft over the others.
Rates of spontaneous resolution of endoleaks as well as
interventions by graft type are presented in Table IV.
Endoleaks resolved at a near constant rate for the first 18
months, after which the rate of spontaneous resolution
decreased. Resolution occurred in 54 (33%) of 164 type II
endoleaks between 1 and 6 months, in 37 (33%) of 112
between 6 and 12 months, in 21 (37%) of 57 from 12 to 24
months, and in 5 (20%) of 25 between 24 and 36 months.
The various grafts had a nearly identical pattern for the
rate of spontaneous resolution but was highest for Talent
(Fig 2).
Evidence of late appearing type II endoleaks was noted
in a significant number of patients. At 6 months, 44 (30%)
of 147 type II endoleaks were newly diagnosed, and the
rate of new endoleaks did not largely change during the
follow-up period. The rates were 37 (35%) of 107 at 12
months, 15 (27%) of 56 at 2 years and 5 (25%) of 20 at 3
years. No conversions to open repair for type II endoleaks
or ruptures were noted in the first 4 years.
DISCUSSION
Endoleaks after EVAR lead to increased surveillance
and increased postoperative interventions. The ability to
elucidate factors that contribute to the formation of the
more common type II endoleaks may allow physicians to
decrease their incidence, resulting in a decrease in subse-
quent imaging or interventions, or both. Assessment for
preoperative anatomic factors has shown a trend toward an
increased incidence of type II endoleaks with multiple
patent side branches on preoperative imaging.4,5 Although
Fig 1. Two-year type II endoleaks by device type.this may be a contributing factor, endoleaks do not developin most patients with patent side branches preoperatively,
making preoperative embolization futile. The reason why
some backflow persists, giving rise to endoleaks in some
patients and not in others, is open to speculation. Reported
rates of type II endoleaks have been quite variable, with
some recent studies reporting rates of6% at either 30 days
or 6 months with some endografts.1,2 One implication is
that even type II endoleaks may be graft-dependent; how-
ever, no multi-institutional studies to date have directly
examined the hypothesis that type II endoleaks after EVAR
are graft-dependent.
Given the variability in graft design and the multitude
of outcomes found to be graft-dependent (ie, aneurysm
shrinkage, limb occlusions),6,7 it is conceivable that type II
endoleaks may be partly related to the endograft used. The
grafts analyzed in this study vary in configuration, fabric
composition, deployment, and fixation patterns. The An-
cure is an unsupported polyester graft that attaches to the
native aorta by proximal hooks. The Zenith graft is a
self-expanding modular Dacron graft supported by Z
stents that uses a suprarenal bare stent with barbs for
fixation. The Lifepath graft is a balloon-expandable par-
tially supported modular polyester graft with external me-
tallic crimps that assist in fixation. The Excluder is a mod-
ular expanded polytetrafluoroethylene endograft with a
self-expanding nitinol exoskeleton. The AneuRx is a mod-
ular, fully supported self-expanding polyester graft with
columnar rigidity. The Talent is a modular polyester graft
with interspersed self-expanding stents.With themany design
variations and different mechanical properties of endografts,
it is plausible that a direct effect on persistence of side
branch flow may exist.
Ouriel et al,3 in a single institution review, showed type
II endoleaks to be dependent on graft type. The Excluder
had a significantly higher incidence of endoleak at 12
months (58%), and the Talent had the lowest rate (19%).
Our review of six different grafts used at five different
institutions showed that rates of initial type II endoleaks
may be different among endografts, but despite compara-
ble rates of intervention, those differences are significantly
blunted over time. The Excluder and Talent had statisti-
cally significant differences in endoleak rates, but this dif-
ference was only significant at 1month for the Excluder and
at 6months for the Talent. By 1 year, the residual rates were
no longer different, although the general trends persisted.
Why the rates of type II endoleaks should be different
among endografts is open to speculation. Most AAA pa-
Table III. Rate of intervention by institution
Institution Interventions (N) Patients (N) Interventions (%)
A 44 809 5.4
B 32 423 7.6
C 15 422 3.6
D 4 137 2.9
E 6 118 5.1tients have side branches, so if the occurrence of endoleaks
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rates of persistence of flow should be similar. Back bleed-
ing, however, is a direct result of a higher pressure in the
branch compared with the aneurysm sac. If the transmis-
sion of pulsatile pressure to the sac is different among stent
grafts, then it would be possible to expect different rates of
type II endoleaks. Fabric type and porosity as well as other
mechanical properties of the device may thus affect the rate
of back bleeding. The new technology of direct pressure
measurement of the sac will help elucidate if these are
contributing factors.
Other explanations have been offered, such as the
ballooning of the fabric off the stents as seen with the
Endologix (Irvine, Calif) graft. Changes in all these factors
over time are expected and probably are reflected in the
frequency of spontaneous resolutions as well as in late-
appearing endoleaks. These observations may also be related
to differential flow in these branches over time, dependent on
pressure gradients.
Retrospective reviews such as the present study do not
control for serious confounding variables. First, methodol-
ogy of CT scanning was not standardized across institu-
tions, and after intervention, artifact may make detection of
an endoleak more difficult. Also, despite the large number
of patients, the anatomic characteristics of the AAAs en-
Fig 2. Resolution of leaks by device in patients with a leak de-
tected during any visit.
Table IV. Rate of intervention and spontaneous resolutio
follow-up at subsequent time point
1-6 months 6-12 month
SR (%) I (%) SR (%)
Ancure 16 (35) 1 (2.2) 9 (36) 8
AneuRx 15 (33) 4 (8.7) 15 (39) 3
Excluder 7 (33) 1 (4.8) 4 (33) 1
Lifepath 4 (50) 0 1 (17) 1
Talent 10 (45) 0 5 (38)
Zenith 2 (9.1) 0 3 (17) 1
SR, Spontaneous resolution; I, intervention.rolled in each arm may be quite different. The Talentdevice, with its larger stent sizes, may have been used
preferentially for large necks associated with larger aneu-
rysms, a higher thrombus burden, and fewer patent branches.
Conversely, the lower-profile Excluder may have been used
primarily in patients with smaller calcified iliacs associated
with smaller aneurysms, less thrombus, and calcified lum-
bars.
Only a randomized trial would prevent selection bias
in assigning truly equivalent patients to all groups. We
expect those differences to be blunted—but not com-
pletely eliminated—by deriving the patients from five dif-
ferent institutions and spreading the bias among the six
endografts. Pooling data across multiple institutions should
better reflect the actual endoleak rates of a given endograft
rather than anatomic biases from a single institution.
The presence of a type II endoleak in itself may not be
of great consequence because many of these resolve quickly
on their own without subjecting the patient to any addi-
tional interventions. Knowing whether a particular en-
dograft has a high or low rate of spontaneous resolution of
type II endoleaks may help the surgeon tailor the need for
additional studies or timing of an intervention. However,
not only were overall rates of endoleaks essentially equiva-
lent, but so were rates of spontaneous resolution and late
endoleak development. The Talent had the highest rate of
spontaneous resolution but did not reach statistical signif-
icance compared with the other grafts. The overall rate of
spontaneous resolution was relatively constant for the first
year and a half, with about one third resolving every 6
months. Thus, a period of surveillance to assess for sponta-
neous resolution of endoleak is a reasonable strategy, espe-
cially since no ruptures were reported in this series, but
resolution is no more likely with any particular graft.
During the early experience of EVAR, the significance
and natural history of endoleaks was not well understood,
thus most patients had an intervention for treatment of
their endoleak. Although aggressive treatment is still war-
ranted for type I endoleaks, more recent data have shown
that most type II endoleaks follow a more indolent course.
As a result, many surgeons have taken a less aggressive
stance in treating these endoleaks; however, exact treat-
ment patterns may vary from surgeon to surgeon. There-
fore, the true rate of spontaneous resolution of the en-
graft type for patients with leak at given time point and
12-24 months 24-36 months
SR (%) I (%) SR (%) I (%)
7 (39) 3 (17) 1 (25) 1 (25)
) 4 (17) 0 1 (7.1) 1 (7.1)
) 2 (40) 0 0 0
1 (100) 0 0 0
5 (83) 0 2 (100) 0
) 2 (50) 0 1 (100) 0n by
s
I (%)
(32)
(7.9
(8.3
(17)
0
(5.5doleak may differ among those patients treated earlier in
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in endoleak treatment philosophy over time also affects the
number of interventions performed in earlier vs later grafts.
Such varying patterns make analysis of late spontaneous
resolution impractical but do not affect the initial reported
incidence of endoleaks.
CONCLUSIONS
Rates of type II endoleaks show some variability between
endografts; however, these differences are not marked and
only significant for few graft types early after implantation.
By 1 year, there are no significant differences in the preva-
lence of type II endoleaks among most endografts.
AUTHOR CONTRIBUTIONS
Conception and design: MKS, KO, RG, RM, MM, MF,
MW, JC, RF, MSM
Analysis and interpretation: MKS, MSM
Data collection: MKS, RG, MM, MW, JC
Writing the article: MKS, MSM
Critical revision of the article: MKS, MSM
Final approval of the article: MKS, KO, RG, RM, MF, JC,
RF, MSM
Statistical analysis: MSM, MKSObtained funding: Not applicable
Overall responsibility: MSM
REFERENCES
1. May J, White GH, Waugh R, Ly CN, Stephen MS, Jones MA, et al.
Improved survival after endoluminal repair with second-generation pros-
theses compared with open repair in the treatment of abdominal aortic
aneurysms: a 5-year concurrent comparison using life table method. J
Vasc Surg 2001;33:S21-6.
2. Carpenter JP. Endologix Investigators. Multicenter trial of the Power-
Link bifurcated system for endovascular aortic aneurysm repair. J Vasc
Surg 2002;36:1129-37.
3. Ouriel K, Clair DG, Greenberg RK, Lyden SP, O’Hara PJ, et al. Endo-
vascular repair of abdominal aortic aneurysms: device-specific outcomes.
J Vasc Surg. 2003; 37:991-8.
4. Back MR, Bowser AN, Johnson BL, Schmacht D, Zwiebel B, Bandyk
DF. Patency of infrarenal aortic side branches determines early aneurysm
sac behavior after endovascular repair. Ann Vasc Surg 2003;17:27-34.
5. Petrik PV, Moore WS. Endoleaks following endovascular repair of ab-
dominal aortic aneurysm: the predictive value of preoperative anatomic
factors—a review of 100 cases. J Vasc Surg 2001;33:739-44.
6. Bertges DJ, Chow K, Wyers MC, Landsittel D, Frydrych AV, Stavropou-
losW, et al. Abdominal aortic aneurysm size regression after endovascular
repair is endograft dependent. J Vasc Surg 2003;37:716-23.
7. Carpenter JP, Neschis DG, Fairman RM, Barker CF, Golden MA,
Velazquez OC, et al. Failure of endovascular abdominal aortic aneurysm
graft limbs. J Vasc Surg 2001;33:296-303.Submitted May 6, 2004; accepted Dec 26, 2005.
